07:55 AM EDT, 09/19/2024 (MT Newswires) -- Acelyrin ( SLRN ) said Thursday that the global late-stage trial of its treatment izokibep in patients with moderate-to-severe hidradenitis suppurativa yielded statistically significant improvement responses across multiple efficacy endpoints.
Shares of the company were up 5% in recent Thursday premarket activity.